The Biliary Tract Cancers Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Biliary Tract Cancers treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Biliary Tract cancer pipeline landscape and fostering the potential growth of Biliary Tract cancer therapeutic advancements.

 

Key Takeaways from the Biliary Tract Cancers Pipeline Report

• DelveInsight’s Biliary Tract Cancers pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Biliary Tract Cancers treatment.
• The leading companies working in the Biliary Tract Cancers market include Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited, and others.
• Promising Biliary Tract Cancers Pipeline Therapies in the various stages of development include M7824, SMT-NK inj.+Pembrolizumab, Durvalumab, mFOLFOX, ZKAB001 5mg/kg, Capecitabine, RC48-ADC, Atezolizumab, Bevacizumab, Lenvatinib, MRG003, Gemcitabine, Cisplatin, and others.
• On September 2023, AstraZenca announced a study of Phase 3 Clinical Trials for Durvalumab. This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator’s choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment.
• On June 2023, InnoPharmax Inc. announced a study of Phase 2 & 3 Clinical Trials for mFOLFOX and D07001-softgel capsules + Xeloda (or TS-1). In phase IIb/III,the first 40 subjects (20 subjects per arm) will be randomly allocated in a 1:1 ratio in two arms. Arm A will receive active symptom control (ASC) with the selected dose from dose-finding stage of D07001-softgel capsules and Xeloda (or TS-1), in 21-day cycles.

 

Request a sample and discover the recent advances in Biliary Tract Cancers Treatment Drugs @ Biliary Tract Cancers Pipeline Report

 

The Biliary Tract Cancers pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Biliary Tract Cancers drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Biliary Tract Cancers clinical trial landscape.

 

Biliary Tract Cancers Overview

Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation.

 

Find out more about Biliary Tract Cancers Treatment Drugs @ Drugs for Biliary Tract Cancers Treatment

 

Biliary Tract Cancers Emerging Drugs Profile

• MRG 002: Miracogen
• Disitamab vedotin: Yantai Rongchang Pharmaceutical
• Envafolimab: Alphamab Oncology
• DKN-01: Leap Therapeutics

 

Biliary Tract Cancers Pipeline Therapeutics Assessment

The Biliary Tract Cancers pipeline report proffers an integral view of the Biliary Tract Cancers emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Biliary Tract Cancers Pipeline Therapies @ Biliary Tract Cancers Clinical Trials Assessment

 

Scope of the Biliary Tract Cancers Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Biliary Tract Cancers Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited, and others.
• Biliary Tract Cancers Pipeline Therapies- M7824, SMT-NK inj.+Pembrolizumab, Durvalumab, mFOLFOX, ZKAB001 5mg/kg, Capecitabine, RC48-ADC, Atezolizumab, Bevacizumab, Lenvatinib, MRG003, Gemcitabine, Cisplatin, and others.

 

Dive deep into rich insights for new drugs for Biliary Tract Cancers Treatment, Visit @ Biliary Tract Cancers Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Biliary Tract Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Biliary Tract Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Envafolimab: Alphamab Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SMT-NK: SMT bio Co., Ltd.
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. HA121-28: CSPC ZhongQi Pharmaceutical Technology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. ZKAB001: Lee’s Pharmaceutical Limited
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Biliary Tract Cancer Key Companies
24. Biliary Tract Cancer Key Products
25. Biliary Tract Cancer- Unmet Needs
26. Biliary Tract Cancer- Market Drivers and Barriers
27. Biliary Tract Cancer- Future Perspectives and Conclusion
28. Biliary Tract Cancer Analyst Views
29. Biliary Tract Cancer Key Companies
30. Appendix

 

For further information on the Biliary Tract Cancers Pipeline therapeutics, reach out to Biliary Tract Cancers Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting